Dysbiosis
Conditions
Brief summary
The objective is to test ex-vivo the effects of two probiotic solutions (Lactibiane ATB and Lactibiane Enfant) and five classes of drugs (antibiotic, proton pump inhibitor, non-steroidal anti-inflammatory, anxiolytic and anti-depressant) on microbial microcosms derived from human stool samples (from adults and children) re-cultured under anaerobic conditions.
Interventions
OTHERStool sampling
1 stool sample is taken during the study with a stool sample kit
Sponsors
Université Paris-Saclay
Larena SAS
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
1 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
Adult Mother population: * Women aged 25-40 years; * In good general health, i.e. no chronic pathology and not taking any medication at the time of inclusion and/or long-term treatment, * With a regular bowel movement frequency (at least once every 2 days) * BMI between 18.5 and 25 * Able and willing to participate in the research by complying with the protocol procedures * Not objecting to the collection and processing of their personal data Child Daughter population * Girl between 1 and 2 years old * In good general health, i.e. no chronic pathology and not taking any medication at the time of inclusion and/or on a long-term basis, * With a regular stool frequency (at least once every 2 days) * Whose mother does not object to the collection and processing of personal data
Exclusion criteria
Adult Mother population : * Pregnant or breastfeeding women, * Under antibiotic treatment, or having stopped it for less than a month. * Under dietary supplementation (prebiotics or probiotics) or having stopped it less than one month before * On antidepressants and/or anxiolytics in the month before inclusion * Taking a non-steroidal anti-inflammatory drug (NSAID) the month before inclusion. * On PPI, or having stopped it less than one month before. * Persons under court protection, * Person participating in another research study with an ongoing exclusion period, Child Daughter population: * Outside the WHO normal growth charts (weight for height) for girls aged 0-2 years (below the 3rd percentile or above the 97th percentile) * Undergoing antibiotic treatment, or having stopped it less than a month ago. * Having taken a non-steroidal anti-inflammatory drug (NSAID) in the month prior to inclusion. * On dietary supplements (prebiotics or probiotics) or having stopped them within the last month * Subjects participating in another research study with an ongoing exclusion period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptional activity of microbiomes | 10 months | Transcriptional activity of microbiomes by sequencing of 16S rRNA vs. the gene encoding 16S rRNA |
| Transcriptomic profiles of the communities | 10 months | Transcriptomic profiles of the communities assessed by meta-transcriptomics |
| Metabolites produced and microbial metabolic pathways | 10 months | Metabolites produced and microbial metabolic pathways will be assessed by global metabolomics |
Countries
France
Outcome results
None listed